CytoDyn Inc CEO Dr. Nader Pourhassan tells Proactive Investors the Washington-based biotech has teaming up with the Thai Red Cross AIDS Research Centre (TRCARC) to conduct a pre-exposure prophylaxis clinical trial of leronlimab (PRO 140) in subjects at high risk of HIV infection.
CytoDyn CEO talks about latest HIV trial featuring its flagship drug, leronlimab
Quick facts: CytoDyn
Market Cap: $152.28 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of CytoDyn named herein, including the promotion by the Company of CytoDyn in any Content on the Site, the Company receives from said issuer...FOR OUR FULL DISCLAIMER CLICK HERE